Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Merck & Company (MRK)

Merck & Company (MRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 302,633,056
  • Shares Outstanding, K 2,482,023
  • Annual Sales, $ 64,168 M
  • Annual Income, $ 17,117 M
  • EBIT $ 22,392 M
  • EBITDA $ 26,891 M
  • 60-Month Beta 0.28
  • Price/Sales 4.57
  • Price/Cash Flow 12.65
  • Price/Book 5.76

Options Overview Details

View History
  • Implied Volatility 26.37% (-0.94%)
  • Historical Volatility 20.61%
  • IV Percentile 18%
  • IV Rank 14.78%
  • IV High 53.48% on 04/10/25
  • IV Low 21.66% on 12/08/25
  • Expected Move (DTE 5) 2.81 (2.30%)
  • Put/Call Vol Ratio 0.49
  • Today's Volume 21,891
  • Volume Avg (30-Day) 36,189
  • Put/Call OI Ratio 0.66
  • Today's Open Interest 607,515
  • Open Int (30-Day) 625,665
  • Expected Range 119.13 to 124.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 0.00
  • Number of Estimates 5
  • High Estimate 2.40
  • Low Estimate -1.52
  • Prior Year 2.22
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
106.03 +15.00%
on 01/28/26
122.66 -0.60%
on 02/06/26
+13.06 (+12.00%)
since 01/06/26
3-Month
85.24 +43.04%
on 11/07/25
122.66 -0.60%
on 02/06/26
+36.15 (+42.14%)
since 11/06/25
52-Week
73.31 +66.32%
on 05/15/25
122.66 -0.60%
on 02/06/26
+33.88 (+38.48%)
since 02/06/25

Most Recent Stories

More News
MRK Q4 Deep Dive: Pipeline Expansion and New Product Launches Shape Guidance

MRK Q4 Deep Dive: Pipeline Expansion and New Product Launches Shape Guidance

MRK : 121.93 (+1.82%)
Stocks Tumble on AI Disruption Fears

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -0.84%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.34%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.55%. March E-mini...

TER : 300.11 (+10.69%)
AMAT : 322.51 (+6.09%)
TRIP : 12.77 (+2.74%)
AVGO : 332.92 (+7.22%)
INTU : 443.77 (+2.04%)
HL : 22.77 (+6.85%)
CDE : 21.44 (+12.19%)
MRK : 121.93 (+1.82%)
EXPE : 236.85 (+2.40%)
FN : 503.99 (+13.84%)
TRI : 88.07 (-0.27%)
ADM : 66.33 (+1.38%)
Software Stocks Retreat and Drag the Broader Market Lower

The S&P 500 Index ($SPX ) (SPY ) today is down -0.35%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.13%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.94%. March E-mini S&P futures (ESH26...

TER : 300.11 (+10.69%)
INTU : 443.77 (+2.04%)
HL : 22.77 (+6.85%)
CDE : 21.44 (+12.19%)
MRK : 121.93 (+1.82%)
FN : 503.99 (+13.84%)
TRI : 88.07 (-0.27%)
ADM : 66.33 (+1.38%)
$IUXX : 25,075.77 (+2.15%)
PFE : 27.22 (+2.76%)
ZNH26 : 112-035s (-0.01%)
ESH26 : 6,952.75s (+1.94%)
Are Wall Street Analysts Bullish on Moderna Stock?

While Moderna has outpaced the S&P 500 over the past year, Wall Street analysts maintain a cautious outlook about the stock’s prospects.

$SPX : 6,932.30 (+1.97%)
MRK : 121.93 (+1.82%)
IBB : 174.98 (+2.91%)
MRNA : 41.01 (+0.34%)
PIPR : 364.38 (+9.88%)
Nasdaq Slips, Gold and Silver Stage Substantial Recovery

The S&P 500 Index ($SPX ) (SPY ) today is down -0.58%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.07%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.24%. Stock indexes are mixed today,...

TER : 300.11 (+10.69%)
AMAT : 322.51 (+6.09%)
AVGO : 332.92 (+7.22%)
HL : 22.77 (+6.85%)
CDE : 21.44 (+12.19%)
ADI : 320.45 (-0.52%)
MRK : 121.93 (+1.82%)
FN : 503.99 (+13.84%)
ADM : 66.33 (+1.38%)
TXN : 221.44 (-1.13%)
$IUXX : 25,075.77 (+2.15%)
PFE : 27.22 (+2.76%)
Merck’s (NYSE:MRK) Q4 CY2025 Sales Beat Estimates

Merck’s (NYSE:MRK) Q4 CY2025 Sales Beat Estimates

MRK : 121.93 (+1.82%)
Merck: Q4 Earnings Snapshot

Merck: Q4 Earnings Snapshot

MRK : 121.93 (+1.82%)
Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline

Reports Strength in Oncology and Animal Health, Plus Increasing Contributions From WINREVAIR and CAPVAXIVE Fourth-Quarter Worldwide Sales Were $16.4 Billion (5% Growth;...

MRK : 121.93 (+1.82%)
Nasdaq Futures Climb on Blowout Palantir Results

March Nasdaq 100 E-Mini futures (NQH26) are trending up +0.41% this morning as forecast-beating quarterly results and guidance from Palantir Technologies boosted sentiment.

TER : 300.11 (+10.69%)
SNDK : 597.95 (+3.77%)
MRK : 121.93 (+1.82%)
MU : 394.69 (+3.08%)
AMUN.P.DX : 78.575 (-0.95%)
RMBS : 107.10 (+9.17%)
AMGN : 384.32 (+4.49%)
PFE : 27.22 (+2.76%)
DIS : 108.70 (+3.55%)
TSLA : 411.11 (+3.50%)
INTC : 50.59 (+4.87%)
NQH26 : 25,163.25s (+2.08%)
Amgen Stock: Is Wall Street Bullish or Bearish?

Are Wall Street analysts bullish or bearish on Amgen’s stock prior to its Q4 earnings release?

XLV : 157.71 (+1.85%)
$SPX : 6,932.30 (+1.97%)
MRK : 121.93 (+1.82%)
AMGN : 384.32 (+4.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 125.13
2nd Resistance Point 123.90
1st Resistance Point 122.91
Last Price 121.93
1st Support Level 120.69
2nd Support Level 119.46
3rd Support Level 118.47

See More

52-Week High 122.66
Last Price 121.93
Fibonacci 61.8% 103.81
Fibonacci 50% 97.99
Fibonacci 38.2% 92.16
52-Week Low 73.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar